Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884000 | 1.00 | KCNA5 (0.48) | KCNA5ABCB1ADRB3ADRA2AADRA2B | |
| SCHEMBL2887648 | 0.93 | KCNA5 (0.50) | KCNA5ABCB1ADRB3IDO1KCNE1 | |
| SCHEMBL2010207 | 0.91 | KCNA5 (0.46) | KCNA5ABCB1ADRB3IDO1 | |
| SCHEMBL2010205 | 0.91 | KCNA5 (0.46) | KCNA5ABCB1ADRB3IDO1 | |
| SCHEMBL5989846 | 0.89 | KCNA5 (0.47) | KCNA5ABCB1ADRB3IDO1KCNE1 | |
| SCHEMBL2883962 | 0.89 | KCNA5 (0.47) | KCNA5ABCB1ADRB3IDO1KCNE1 | |
| SCHEMBL2889416 | 0.88 | KCNA5 (0.47) | KCNA5ABCB1IDO1KCNE1KCNQ1 | |
| SCHEMBL2889419 | 0.88 | KCNA5 (0.47) | KCNA5ABCB1IDO1KCNE1KCNQ1 | |
| SCHEMBL2889459 | 0.85 | KCNA5 (0.47) | KCNA5ABCB1IDO1 | |
| SCHEMBL2889456 | 0.85 | KCNA5 (0.47) | KCNA5ABCB1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | claimed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | KCNA5 69/4885ABCB1 978/4885ADRB3 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.